EPS

Beyond record profits, Advanced Energy's Q2 results show how foundational tech, not just algorithms, is fueling the AI and data center explosions.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

Amid interest rate volatility, Invesco Mortgage Capital adds a seasoned financial expert to its board, a move signaling a push for enhanced risk oversight.

Strong performance from its Industrial Equipment division, boosted by a key acquisition, helps Alamo Group navigate mixed market conditions and post solid Q2 results.

As Sonida Senior Living prepares its Q2 results, investors are watching closely. Can the operator prove its massive merger is paying off amidst industry-wide cost pressures?

InsCorp (IBTN) reports a 14% quarterly EPS jump, driven by its new Murfreesboro expansion hitting breakeven far ahead of schedule. A deep dive into the strategy.

The energy giant's massive new repurchase authorization highlights robust financial health and a multi-faceted strategy balancing shareholder returns with growth.

With record fundraising and a massive $170 billion in dry powder, Ares is not just navigating a slow market—it's preparing to reshape it. Here's the strategy.

While global auto production sputters, Magna International posts record earnings and raises its outlook. A deep dive into the operational discipline behind the numbers.

As specialty insurer Trisura Group readies its Q2 results, investors are watching to see if its growth can navigate market shifts and justify high expectations.

The precision instrument maker posted a 14% jump in adjusted EPS, driven by Asian markets and its Spinnaker program, while managing a one-time tariff event.

As Q2 results show a legacy business in decline and margin pressure mounting, Western Union bets its future on a digital pivot and aggressive cost-cutting.

The utility giant's strong Q2 earnings, powered by regulatory wins, signal financial stability. The real signal is its high-tech strategy to manage risk.

A massive tariff refund inflated Columbia's earnings, masking U.S. weakness while its new strategy to woo younger shoppers shows early promise.

As CapsoVision preps its Q2 report, investors look past the numbers to its AI-driven pipeline, a key test of its strategy to reshape GI diagnostics.

Advantage Energy's Q2 results signal a major shift. After completing a capital-intensive infrastructure build, the firm is now poised for robust free cash flow.

Beyond stellar earnings, CNO Financial’s 16-quarter growth streak reveals a potent strategy of human investment and innovation for a vital, often-overlooked market.

As ARKO Corp. preps its Q2 report, all eyes are on whether its recent strategic overhaul, including the IPO of its fuel arm, can deliver growth.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

With a $1.2B war chest from its Aerospace sale, TriMas boosts profits and shareholder returns. A closer look reveals the next phase of its reinvention.